426 related articles for article (PubMed ID: 20049829)
1. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease.
Kulkarni PV; Roney CA; Antich PP; Bonte FJ; Raghu AV; Aminabhavi TM
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(1):35-47. PubMed ID: 20049829
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticulate radiolabelled quinolines detect amyloid plaques in mouse models of Alzheimer's disease.
Roney CA; Arora V; Kulkarni PV; Antich PP; Bonte FJ
Int J Alzheimers Dis; 2010 Jan; 2009():. PubMed ID: 20721294
[TBL] [Abstract][Full Text] [Related]
3. Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease.
Opazo C; Luza S; Villemagne VL; Volitakis I; Rowe C; Barnham KJ; Strozyk D; Masters CL; Cherny RA; Bush AI
Aging Cell; 2006 Feb; 5(1):69-79. PubMed ID: 16441845
[TBL] [Abstract][Full Text] [Related]
4. Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease.
Kung MP; Hou C; Zhuang ZP; Skovronsky D; Kung HF
Brain Res; 2004 Oct; 1025(1-2):98-105. PubMed ID: 15464749
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation.
Kandimalla KK; Curran GL; Holasek SS; Gilles EJ; Wengenack TM; Poduslo JF
J Pharmacol Exp Ther; 2005 Jun; 313(3):1370-8. PubMed ID: 15743932
[TBL] [Abstract][Full Text] [Related]
7. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies.
Joshi SA; Chavhan SS; Sawant KK
Eur J Pharm Biopharm; 2010 Oct; 76(2):189-99. PubMed ID: 20637869
[TBL] [Abstract][Full Text] [Related]
8. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles.
Kurakhmaeva KB; Djindjikhashvili IA; Petrov VE; Balabanyan VU; Voronina TA; Trofimov SS; Kreuter J; Gelperina S; Begley D; Alyautdin RN
J Drug Target; 2009 Sep; 17(8):564-74. PubMed ID: 19694610
[TBL] [Abstract][Full Text] [Related]
9. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer's disease.
Roney C; Kulkarni P; Arora V; Antich P; Bonte F; Wu A; Mallikarjuana NN; Manohar S; Liang HF; Kulkarni AR; Sung HW; Sairam M; Aminabhavi TM
J Control Release; 2005 Nov; 108(2-3):193-214. PubMed ID: 16246446
[TBL] [Abstract][Full Text] [Related]
10. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
Wilson B; Samanta MK; Santhi K; Kumar KP; Paramakrishnan N; Suresh B
Brain Res; 2008 Mar; 1200():159-68. PubMed ID: 18291351
[TBL] [Abstract][Full Text] [Related]
11. [Introduction to and general remarks on molecular imaging].
Fukuda H; Okamura N
Brain Nerve; 2007 Mar; 59(3):203-7. PubMed ID: 17370645
[TBL] [Abstract][Full Text] [Related]
12. In vivo labelling of hippocampal beta-amyloid in triple-transgenic mice with a fluorescent acetylcholinesterase inhibitor released from nanoparticles.
Härtig W; Kacza J; Paulke BR; Grosche J; Bauer U; Hoffmann A; Elsinghorst PW; Gütschow M
Eur J Neurosci; 2010 Jan; 31(1):99-109. PubMed ID: 20092557
[TBL] [Abstract][Full Text] [Related]
13. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice.
van Groen T; Kiliaan AJ; Kadish I
Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076
[TBL] [Abstract][Full Text] [Related]
14. Styryl-based compounds as potential in vivo imaging agents for beta-amyloid plaques.
Li Q; Min J; Ahn YH; Namm J; Kim EM; Lui R; Kim HY; Ji Y; Wu H; Wisniewski T; Chang YT
Chembiochem; 2007 Sep; 8(14):1679-87. PubMed ID: 17705341
[TBL] [Abstract][Full Text] [Related]
15. Diphenylpropynone derivatives as probes for imaging β-amyloid plaques in Alzheimer's brains.
Ono M; Watanabe H; Watanabe R; Haratake M; Nakayama M; Saji H
Bioorg Med Chem Lett; 2011 Jan; 21(1):117-20. PubMed ID: 21145738
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research.
Jack CR; Marjanska M; Wengenack TM; Reyes DA; Curran GL; Lin J; Preboske GM; Poduslo JF; Garwood M
Neuroscientist; 2007 Feb; 13(1):38-48. PubMed ID: 17229974
[TBL] [Abstract][Full Text] [Related]
17. ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model.
Mulik RS; Mönkkönen J; Juvonen RO; Mahadik KR; Paradkar AR
Mol Pharm; 2010 Jun; 7(3):815-25. PubMed ID: 20230014
[TBL] [Abstract][Full Text] [Related]
18. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta.
Adlard PA; Cherny RA; Finkelstein DI; Gautier E; Robb E; Cortes M; Volitakis I; Liu X; Smith JP; Perez K; Laughton K; Li QX; Charman SA; Nicolazzo JA; Wilkins S; Deleva K; Lynch T; Kok G; Ritchie CW; Tanzi RE; Cappai R; Masters CL; Barnham KJ; Bush AI
Neuron; 2008 Jul; 59(1):43-55. PubMed ID: 18614028
[TBL] [Abstract][Full Text] [Related]
19. Novel 18F-labeled benzofuran derivatives with improved properties for positron emission tomography (PET) imaging of β-amyloid plaques in Alzheimer's brains.
Ono M; Cheng Y; Kimura H; Cui M; Kagawa S; Nishii R; Saji H
J Med Chem; 2011 Apr; 54(8):2971-9. PubMed ID: 21428407
[TBL] [Abstract][Full Text] [Related]
20. Amyloid imaging: from benchtop to bedside.
Wu C; Pike VW; Wang Y
Curr Top Dev Biol; 2005; 70():171-213. PubMed ID: 16338342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
